Earnings analysis of drugmakers' quarterly results, in-depth business analysis and the CompePharma View, ten new pieces every day.
The strongest results this season came from extending assets already in market, through new labels, formulations and royalties, rather than from unproven launches. That strategy has a ceiling.
Medicare's full-rate payment for EsoGuard is a milestone, but case-by-case coverage and a pending reconsideration show why payer access, not list price, decides the economics.
Longeveron, Theriva and Silence show how much optionality depends on when boards start thinking about the endgame. The best time is before the data arrive.
This week's deals show buyers paying for proof or proven sales, while assets stuck between the two are sold for parts or put up for sale.
From TransMedics to Ultragenyx, the Q3 results separate businesses that pay for their plans from those that still ask investors to wait. Funding has become the strategy.
This week's licences in Japan, Australasia, ASEAN and the Mediterranean show small companies can fund and de-risk without selling the whole asset, provided they hold on to the rights that set the value.
Q3 results split into companies whose current numbers carry the story and those leaning on the future tense. Long-range ambition is only worth what the near-term print backs up.
From Heron's asset sale to Frontage's Exton units and Japan-only licences, this week's deals cut assets into pieces. How the pieces are cut now matters as much as who buys them.
This week's deals share a feature that headlines skip: the value depends on a stretch of time between signing and closing, and leaders should manage that stretch like a project.
Top lines are strong and guidance is rising, but GAAP and adjusted results are diverging in both directions. The companies that show the bridge will earn the credibility.
Commercial-stage biotechs grabbed the headlines, but the earnings with the most forward information came from the company that sells to drug developers, not the ones selling to patients.
From Edesa to Charles River, the sticker price says little. Upfront cash, earn-outs and closing conditions show who is actually carrying the risk.
Harmony, TG, Madrigal and BioMarin all paired strong quarters with dated plans to widen what their lead medicines can do. Investors should expect that pairing from every franchise.
BioMarin's 32% jump and ANI's pursuit of Egetis show M&A now drives reported momentum. Leaders should separate what they built from what they bought.
This season's strongest results come from companies leaning hard on a single franchise. That is a strategy, not an accident, and it deserves to be managed like one.
From Madrigal's patient base to Harmony's net adds, the strongest third quarters rest on volume that can be counted, and the industry should disclose more of it.
This season's guidance moves, raised, narrowed or simply reiterated, say more about management confidence than the quarterly beats do, and the best ones are product-specific and tight.
Third-quarter results from six commercial-stage biotechs show product revenue funding late-stage R&D, deals and buybacks without a capital-markets visit. Leaders should plan around that.
Across five reporters, the biggest product lines carried the quarter. Raised guidance came from established franchises, so the case for protecting and extending them is stronger than the launch narrative suggests.
Commercial results from Moderna, PTC, Sarepta, Acadia and Halozyme are strong. Each release also points to the clinical or regulatory event that will define what comes next.
From Biogen's GAAP loss to Sarepta's operating swing, the gap between reported and adjusted results is now a leadership test. Companies that explain it plainly earn more trust than those that merely close it.
Halozyme, Moderna and Sarepta show that the strongest guidance revisions pair growth with cost discipline. Top-line momentum alone is no longer the headline.
From Viatris to Protagonist, companies are returning cash and buying assets in the same release. The credible ones will be those that state the order of priority.
Halozyme, Protagonist and BeOne show that the best results come from owning scale or from holding well-written claims on someone else's. Leaders should audit which they have.